Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Sponsor: Joseph C. Wu
Summary
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Official title: Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2026-01-01
Completion Date
2029-01-01
Last Updated
2026-01-09
Healthy Volunteers
No
Conditions
Interventions
Artesunate
Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
Locations (1)
Stanford University
Stanford, California, United States